Added to YB: 2026-09-21
Pitch date: 2026-09-17
MSLE [neutral]
Satellos Bioscience Inc.
-4.12%
current return
Author Info
No bio for this author
Company Info
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia.
Market Cap
CAD 197.3M
Pitch Price
CAD 9.72
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.78
P/E
-4.67
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Biotech Conferences Week 2 Day 3 Part 2 - Satellos Bioscience Inc.
MSLE (quick overview): Satellos’ forzaptin is a differentiated, oral, mutation-agnostic DMD candidate intended to restore muscle regeneration alongside existing therapies. Encouraging Trailhead biomarker, respiratory, strength and MRI observations come from only four to five adults and remain hypothesis-generating. The investment case depends overwhelmingly on the 51-boy, placebo-controlled Basecamp dataset in early 2027 showing coherent biological and functional benefit; just over $60 million of cash should cover that readout, but runway ends shortly afterward.
Read full article (2 min)